Personalized Drug Development: Strategic And Operational Insights For Biopharma, Payers And Providers From A Large Survey Of United States And Eu Decision Makers

Abstract

lenges and opportunities. Results: Only 22%-27% of payers and providers believe that personalized medicine is a "very important" strategic goal versus ~50% of large biopharma manufacturers. Although 47%-52% of all stakeholders have integrated staff with area expertise, fewer than 20% have developed a centralized focus on personalized medicine and only 8%-20% believe they have tools to evaluate its success. Decision maker perspectives ranged broadly on its key benefits but included improved and more predictable outcomes and cost efficiencies. Approximately 30% of all stakeholders believe that personalized medicines will continue to receive premium pricing to justify ROI for this business approach. ConClusions: Although most stakeholders see value in personalized medicines, they struggle with practical implementation and need actionable strategies to characterize the value and impact of these technologies. The survey suggests that limited emphasis on infrastructure development and methods, heterogeneous value assessment, and misalignment of incentives remain key challenges to enabling care and economic efficiencies promised by this evolving treatment paradigm.